EA202190993A2 - Стероиды c-19 для ингибирования неоваскуляризации - Google Patents

Стероиды c-19 для ингибирования неоваскуляризации

Info

Publication number
EA202190993A2
EA202190993A2 EA202190993A EA202190993A EA202190993A2 EA 202190993 A2 EA202190993 A2 EA 202190993A2 EA 202190993 A EA202190993 A EA 202190993A EA 202190993 A EA202190993 A EA 202190993A EA 202190993 A2 EA202190993 A2 EA 202190993A2
Authority
EA
Eurasian Patent Office
Prior art keywords
steroids
inhibiting neovascularization
neovascularization
androsten
proliferation
Prior art date
Application number
EA202190993A
Other languages
English (en)
Other versions
EA202190993A3 (ru
Inventor
Герхард Унтереггер
Original Assignee
Курадис Гмбх
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Курадис Гмбх filed Critical Курадис Гмбх
Publication of EA202190993A2 publication Critical patent/EA202190993A2/ru
Publication of EA202190993A3 publication Critical patent/EA202190993A3/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
    • A61K31/5685—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone having an oxo group in position 17, e.g. androsterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Immunology (AREA)
  • Obesity (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Vascular Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Urology & Nephrology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Pain & Pain Management (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Изобретение относится к области медицины, в частности к принципиально новым применениям стероидных соединений С-19, имеющих структуру андростен-17-(OR4)-3-онов, для ингибирования ангиогенеза и, в частности, пролиферации и/или миграции эндотелиальных клеток в лечении заболеваний, связанных с патологической неоваскуляризацией и/или избыточными регенеративными процессами.
EA202190993A 2014-12-30 2015-12-21 Стероиды c-19 для ингибирования неоваскуляризации EA202190993A3 (ru)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP14200543.8A EP3040075B1 (en) 2014-12-30 2014-12-30 C-19 steroids for inhibiting neovascularization

Publications (2)

Publication Number Publication Date
EA202190993A2 true EA202190993A2 (ru) 2021-08-31
EA202190993A3 EA202190993A3 (ru) 2021-10-29

Family

ID=52146363

Family Applications (2)

Application Number Title Priority Date Filing Date
EA201791209A EA039485B1 (ru) 2014-12-30 2015-12-21 Применение 4-гидрокситестостерона в качестве ингибитора ангиогенеза
EA202190993A EA202190993A3 (ru) 2014-12-30 2015-12-21 Стероиды c-19 для ингибирования неоваскуляризации

Family Applications Before (1)

Application Number Title Priority Date Filing Date
EA201791209A EA039485B1 (ru) 2014-12-30 2015-12-21 Применение 4-гидрокситестостерона в качестве ингибитора ангиогенеза

Country Status (17)

Country Link
US (1) US10426785B2 (ru)
EP (2) EP3040075B1 (ru)
JP (1) JP6788592B2 (ru)
KR (1) KR102481553B1 (ru)
CN (2) CN107206010B (ru)
CA (1) CA2972324C (ru)
DK (1) DK3040075T3 (ru)
EA (2) EA039485B1 (ru)
ES (1) ES2651442T3 (ru)
HR (1) HRP20171875T1 (ru)
HU (1) HUE037698T2 (ru)
NO (1) NO3040075T3 (ru)
PL (1) PL3040075T3 (ru)
PT (1) PT3040075T (ru)
RS (1) RS56621B1 (ru)
SI (1) SI3040075T1 (ru)
WO (1) WO2016107778A1 (ru)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3632445A1 (en) * 2018-10-04 2020-04-08 Curadis GmbH Combinations with a c-19 steroid for treating cancers
CN114149923B (zh) * 2021-11-19 2024-03-08 大连理工大学 内皮细胞-平滑肌细胞共培养的单流道微芯片模型的构建方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5504074A (en) * 1993-08-06 1996-04-02 Children's Medical Center Corporation Estrogenic compounds as anti-angiogenic agents
RS20150135A1 (en) * 2003-05-30 2015-08-31 Genentech Inc. TREATMENT WITH ANTI-VEGF ANTIBODIES
CA2558014A1 (en) * 2004-03-12 2005-09-29 Entremed, Inc. Antiangiogenic agents
US20060264413A1 (en) * 2005-04-18 2006-11-23 Sri International Method and composition for inhibiting cell proliferation and angiogenesis
EP1854465A1 (en) * 2006-05-12 2007-11-14 Alexander Tobias Teichmann Use of 4,17 beta-dihydroxyandrost-4-ene-3-one for treating cancers
ES2547339T3 (es) * 2007-11-13 2015-10-05 Curadis Gmbh Esteroides C-19 para usos terapéuticos específicos
CN101619089B (zh) * 2009-07-28 2011-07-20 陈大刚 抗肿瘤药物cl168、其合成方法及应用

Also Published As

Publication number Publication date
EA201791209A1 (ru) 2017-11-30
EA202190993A3 (ru) 2021-10-29
EP3040075B1 (en) 2017-09-13
US20170360804A1 (en) 2017-12-21
US10426785B2 (en) 2019-10-01
KR20170100539A (ko) 2017-09-04
EP3215161A1 (en) 2017-09-13
CA2972324A1 (en) 2016-07-07
RS56621B1 (sr) 2018-03-30
HRP20171875T1 (hr) 2018-01-26
JP6788592B2 (ja) 2020-11-25
DK3040075T3 (en) 2017-12-18
ES2651442T3 (es) 2018-01-26
WO2016107778A1 (en) 2016-07-07
EP3040075A1 (en) 2016-07-06
CN107206010B (zh) 2021-12-21
NO3040075T3 (ru) 2018-02-10
SI3040075T1 (en) 2018-04-30
KR102481553B1 (ko) 2022-12-26
CN107206010A (zh) 2017-09-26
PL3040075T3 (pl) 2018-03-30
CN113117089A (zh) 2021-07-16
PT3040075T (pt) 2017-12-20
CA2972324C (en) 2023-09-26
HUE037698T2 (hu) 2018-09-28
JP2018508474A (ja) 2018-03-29
EA039485B1 (ru) 2022-02-01

Similar Documents

Publication Publication Date Title
NI201700019A (es) Anticuerpos anti tigit
BR112017006664A2 (pt) terapias de combinação
BR112017013176A2 (pt) receptores de antígenos quiméricos e métodos para usá-los
DK3172227T3 (da) Molekyler der selektivt aktiverer regulatoriske t-celler til behandlingen af autoimmune sygdomme
EA201692109A1 (ru) Варианты антител к фактору d и их применение
EA201790932A1 (ru) Дозировка и введение нефукозилированных анти-cd40 антител
MA41449A (fr) Polythérapies pour le traitement de cancers
EA201692529A1 (ru) Способы и композиции для лечения расстройств с использованием фоллистатиновых полипептидов
EA201691594A1 (ru) Циклопропиламины в качестве ингибиторов lsd1
BR112017007012A2 (pt) compostos anti-tnf
MA39748A (fr) Cenicriviroc pour le traitement de la fibrose
PH12017500401A1 (en) Therapeutic compounds as inhibitors of the orexin-1 receptor
EA201890185A1 (ru) Способы лечения опосредованных гепсидином нарушений
BR112017006520A2 (pt) métodos de tratamento do lúpus eritematoso sistêmico usando um anticorpo de domínio direcionado contra cd28
EA201591648A1 (ru) Бензимидазол-2-ил-пиримидиновые модуляторы рецептора гистамина h4
EA201790650A1 (ru) Лекарственная форма и способы применения абиратерона ацетата
EA202193002A2 (ru) Соединение, нацеленное на ил-23a и фно-альфа, и его применение
BR112017008672A2 (pt) anticorpos de il-6 melhorados
FI20145484A (fi) Anodiliejun hydrometallurginen käsittely
EA201691887A1 (ru) Лечение внутрипеченочных холестатических заболеваний
CY1123116T1 (el) Θεραπευτικη αντιμετωπιση των αυτοανοσων διαταραχων με cd154 αντισωματα
HK1248140A1 (zh) 用於治療癌症或免疫性疾病的細胞外基質組合物
EA201791249A1 (ru) Получаемые из cd44v6 циклические пептиды для лечения злокачественных опухолей и связанных с ангиогенезом заболеваний
CY1123284T1 (el) Συνθεση που περιλαμβανει υδροκορτιζονη
EA202190993A2 (ru) Стероиды c-19 для ингибирования неоваскуляризации